Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-13T19:27:11.768Z Has data issue: false hasContentIssue false

A service for patients with Wilson's disease

Published online by Cambridge University Press:  02 January 2018

T. R. Dening
Affiliation:
Department of Psychiatry
G. E. Berrios
Affiliation:
University of Cambridge Clinical School
C. A. Seymour
Affiliation:
University of Cambridge Clinical School
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Wilson's disease (WD) is an autosomal recessive disorder of copper metabolism with an incidence of about 30 per million (i.e. fewer than 2,000 in the UK). Nevertheless, it is important for two main reasons: its manifestations are protean and may lead it to present to a range of specialists; and its otherwise lethal course can be halted by treatment with chelating agents such as penicillamine and trientine. Published cases and systematic study have shown that neuropsychiatric symptomatology is important in a high proportion. In fact, about one-fifth either present psychiatrically or are at least seen by a psychiatrist before WD is diagnosed.

Type
Articles
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1988

References

1. Dening, T. R. (1985) Psychiatric aspects of Wilson's disease. British Journal of Psychiatry, 146, 677682.Google Scholar
2. Dening, T. R., Berrios, G. E. & Walshe, J. M. (1988) Wilson's disease and epilepsy. Brain, 111, 11611177.Google Scholar
3. Walshe, J. M. (1956) Penicillamine, a new oral therapy for Wilson's disease. American Journal of Medicine, 21, 487495.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.